BYGGMA ASA (BMA.OL) Stock Fundamental Analysis
Europe - OSL:BMA - NO0003087603 - Common Stock
14.9 NOK
+0.5 (+3.47%)
Taking everything into account, BMA scores 1 out of 10 in our fundamental rating. BMA was compared to 21 industry peers in the Building Products industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BMA had negative earnings in the past year.
BMA had a positive operating cash flow in the past year.
Of the past 5 years BMA 4 years were profitable.
Each year in the past 5 years BMA had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.03%, BMA is doing worse than 81.82% of the companies in the same industry.
Looking at the Return On Equity, with a value of -9.11%, BMA is doing worse than 77.27% of the companies in the same industry.
The Return On Invested Capital of BMA (2.29%) is worse than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.03% | ||
| ROE | -9.11% | ||
| ROIC | 2.29% |
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 2.99%, BMA is doing worse than 81.82% of the companies in the same industry.
With a decent Gross Margin value of 49.71%, BMA is doing good in the industry, outperforming 72.73% of the companies in the same industry.
BMA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.99% | ||
| PM (TTM) | N/A | ||
| GM | 49.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMA is destroying value.
BMA has about the same amout of shares outstanding than it did 1 year ago.
BMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BMA is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.45, we must say that BMA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BMA (1.45) is worse than 68.18% of its industry peers.
BMA has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
BMA has a worse Debt to Equity ratio (1.14) than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.45 |
ROIC/WACC0.26
WACC8.78%
2.3 Liquidity
BMA has a Current Ratio of 0.78. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
BMA has a worse Current ratio (0.78) than 86.36% of its industry peers.
A Quick Ratio of 0.41 indicates that BMA may have some problems paying its short term obligations.
With a Quick ratio value of 0.41, BMA is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
The earnings per share for BMA have decreased strongly by -41.76% in the last year.
Looking at the last year, BMA shows a quite strong growth in Revenue. The Revenue has grown by 8.19% in the last year.
Measured over the past years, BMA shows a small growth in Revenue. The Revenue has been growing by 3.98% on average per year.
EPS 1Y (TTM)-41.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.49%
Revenue 1Y (TTM)8.19%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%8.04%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
BMA's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. BMA is more expensive than 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.69 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:BMA (10/31/2025, 7:00:00 PM)
14.9
+0.5 (+3.47%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.71%
Ins Owner ChangeN/A
Market Cap1.04B
Revenue(TTM)2.31B
Net Income(TTM)-94279000
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.45 | ||
| P/FCF | N/A | ||
| P/OCF | 40.91 | ||
| P/B | 1.01 | ||
| P/tB | 1.02 | ||
| EV/EBITDA | 13.69 |
EPS(TTM)-1.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)0.36
OCFY2.44%
SpS33.02
BVpS14.81
TBVpS14.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.03% | ||
| ROE | -9.11% | ||
| ROCE | 3.47% | ||
| ROIC | 2.29% | ||
| ROICexc | 2.32% | ||
| ROICexgc | 2.33% | ||
| OM | 2.99% | ||
| PM (TTM) | N/A | ||
| GM | 49.71% | ||
| FCFM | N/A |
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
F-Score5
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.54 | ||
| Cap/Depr | 71.91% | ||
| Cap/Sales | 2.74% | ||
| Interest Coverage | 0.7 | ||
| Cash Conversion | 16.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.78 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | 1.45 |
F-Score5
WACC8.78%
ROIC/WACC0.26
Cap/Depr(3y)82.97%
Cap/Depr(5y)85.75%
Cap/Sales(3y)3.16%
Cap/Sales(5y)3.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.49%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.19%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%8.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y138.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-130.75%
FCF growth 3Y-35.16%
FCF growth 5YN/A
OCF growth 1Y-89.51%
OCF growth 3Y-28.69%
OCF growth 5Y-8.56%
BYGGMA ASA / BMA.OL FAQ
What is the ChartMill fundamental rating of BYGGMA ASA (BMA.OL) stock?
ChartMill assigns a fundamental rating of 1 / 10 to BMA.OL.
Can you provide the valuation status for BYGGMA ASA?
ChartMill assigns a valuation rating of 0 / 10 to BYGGMA ASA (BMA.OL). This can be considered as Overvalued.
Can you provide the profitability details for BYGGMA ASA?
BYGGMA ASA (BMA.OL) has a profitability rating of 2 / 10.